New Issue | Current Neuropharmacology ; Volume 18 Issue 2




Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.

The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.


Articles from the journal: Current Neuropharmacology; Volume 18 Issue 2

For details on the articles, please visit this link:

Advertise your event with Bentham Science




We have recently enhanced our advertising package which will help you generate a specific type of user action, such as registering to the event and will boost your online presence.

Bentham Science is an established STM publisher of over 100 scholarly journals and more than 800 books. Our publications cover 20 broad disciplines with a major focus on pharmaceutical and healthcare research. Our journals are indexed in all major indexing agencies including PubMed, Scopus, Web of Science, Clarivate Analytics etc. You can learn more about our high impact journals here.

To promote your event, we are offering online advertising services on our website and online (email campaigns and social media campaigns) channels for various scientific conferences (we have 500,000 visits/traffic per day). Our online platforms would be a good match for your conference, and will allow you to reach your target audience. More information is available on our 2019 Media Pack.


Email campaign to subscribers & contributors in the relevant field, you can custom select the audience as per your event (4,000 to 5,000 email recipients per campaign)

*We have a list of 17,000 Editorial Board Members, 200,000 Bentham Science Contributors and 15,000 other subscribers

Our targeting criteria include:

  • Areas of Work (Oncology, Clinical Research, Pharmacology, Neuroscience, Molecular Biology, etc.)
  • Geography (USA, Europe, Asia, ME/Africa and RoW)
  • Job Titles
  • Institution Type (Academic / Commercial)

CPC Banner advertisements (First 10 clicks will be free of cost)

  • Banner advertisement on scholarly article pages of a relevant journal (above 50 impressions per day for each banner)
  • Banner advertising on Table of content alert to about 3000 contacts per month which include our Editorial Board Members, Subscribers and Contributors
  • Banner advertisement on the home page of a relevant journal
  • Banner advertisement on the home page of relevant eBooks to your preference
  • Company logo on Media Partners section
  • Banner advertisement under the partnering events section on Bentham Science website (Complimentary with the Package)

Social Media Campaign for the event (above 500 post impressions on Bentham Science official Twitter and Facebook)

In addition, we will provide you a detailed report regarding the performance of the ads, including the stats for the following:


✔Clicks and CTR

✔Conversions (where possible)

You can also avail Print Advertising and Customized Email Promotion Packages with nominal costs that best suit your requirements. For details about the Packages and costs please contact at

Wishing you a very Happy Birthday | Prof. Kenneth Maise


Prof Kenneth Maiese.jpg

Prof. Kenneth Maise

Editor-in-Chief: Current Neurovascular Research


Neurology and Neurosciences UMDNJ
205 South Orange Avenue, F1220
Newark, NJ 07101

Article by Disease – “Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair”

Article by Disease on “Neuroscience


The blood-brain barrier (BBB) is a physiological regulator of transport of essential items from blood to brain for the maintenance of homeostasis of the central nervous system (CNS) within narrow limits. The BBB is also responsible for export of harmful or metabolic products from brain to blood to keep the CNS fluid microenvironment healthy. However, noxious insults to the brain caused by trauma, ischemia or environmental/chemical toxins alter the BBB function to small as well as large molecules e.g., proteins. When proteins enter the CNS fluid microenvironment, development of brain edema occurs due to altered osmotic balance between blood and brain. On the other hand, almost all neurodegenerative diseases and traumatic insults to the CNS and subsequent BBB dysfunction lead to edema formation and cell injury. To treat these brain disorders suitable drug therapy reaching their brain targets is needed. However, due to edema formation or only a focal disruption of the BBB e.g., around brain tumors, many drugs are unable to reach their CNS targets in sufficient quantity. This results in poor therapeutic outcome. Thus, new technology such as nanodelivery is needed for drugs to reach their CNS targets and be effective. In this review, use of nanowires as a possible novel tool to enhance drug delivery into the CNS in various disease models is discussed based on our investigations. These data show that nanowired delivery of drugs may have superior neuroprotective ability to treat several CNS diseases effectively indicating their role in future therapeutic strategies.

Read more:

Highlighted Article Flyer for the journal “CNS & Neurological Disorders – Drug Targets”


Highlighted Article Flyer for the journal “CNS & Neurological Disorders – Drug Targets”

CNS & ND-Articles_15-5- Hua Liu

Highlighted Article Flyer for the journal “Current Neuropharmacology”

CN-Articles_14-4- A G Lewis

Highlighted Article Flyer for the journal “Current Aging Science”

CAS-Articles-9-3-Koji Nishio

Highlighted Article Flyer for the journal “Current Neuropharmacology”

CN-Articles_14-4-Xiao-Ping Wang

Highlighted Article Flyer for the journal “Current Neuropharmacology”

CN-Articles_14-4- A -Yekta Ozer

%d bloggers like this: